Short Communication: Liver Toxicity of Lopinavir-Containing Regimens in HIV-Infected Patients with or without Hepatitis C Coinfection
- 1 July 2004
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 20 (7) , 698-700
- https://doi.org/10.1089/0889222041524562
Abstract
Liver toxicity is a common side effect of antiretroviral therapy, particularly in subjects coinfected with the hepatitis C virus (HCV). The incidence of severe liver toxicity after initiation of treatment with lopinavir (LPV) as well as its possible association with LPV plasma levels were assessed in 120 HIV-infected patients (52% coinfected by HCV). The incidence of severe liver toxicity at 3 months was 1.7% and the cumulative incidence at 12 months was 4%. The development of severe liver toxicity was associated with HCV coinfection but not with LPV plasma levels.Keywords
This publication has 17 references indexed in Scilit:
- Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination TherapyThe Journal of Infectious Diseases, 2002
- Hepatotoxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIVJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAARTJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Risk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Risk Factors for Hepatotoxicity in Patients Treated With Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2001
- Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infectionAIDS, 2000
- Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2000
- Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus InfectionJAMA, 2000
- Hepatotoxicity after introduction of highly active antiretroviral therapyAIDS, 1998